| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,150 | 7,200 | 12.08. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 35,000 | 6 | |||
| 33,000 | 33 | |||
| 22,200 | 30 | |||
| 15,000 | 15 | |||
| 11,000 | 500 | |||
| 6,350 | 500 | |||
| 6,100 | 715 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/88q.htm [/URL] | ||||
| 715 | 5,800 | |||
| 700 | 4,740 | |||
| 1.061 | 0,001 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 2.476 | 0,727 | 1.799 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
Keine Umsätze verfügbar. | ||
| Tagesumsatz Xetra | +0,200 +3,45 % | 0 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 4BASEBIO Aktie jetzt für 0€ handeln | |||||
| 22.07. | 4basebio Plc - Grant of Options & Director/PDMR Dealing | 366 | PR Newswire | 4basebio Plc - Grant of Options & Director/PDMR Dealing
PR Newswire
LONDON, United Kingdom, July 22
4basebio PLC
("4basebio"... ► Artikel lesen | |
| 08.07. | 4basebio Plc - Director Appointment | 581 | PR Newswire | 4basebio Plc - Director Appointment
PR Newswire
LONDON, United Kingdom, July 08
4basebio PLC
("4basebio" or the "Company")
... ► Artikel lesen | |
| 30.06. | 4basebio Plc - Result of AGM & Issue of Options | 418 | PR Newswire | 4basebio Plc - Result of AGM & Issue of Options
PR Newswire
LONDON, United Kingdom, June 30
4basebio PLC
("4basebio"... ► Artikel lesen | |
| 16.06. | 4basebio Plc - Notice of Investor Presentation | 408 | PR Newswire | 4basebio Plc - Notice of Investor Presentation
PR Newswire
LONDON, United Kingdom, June 16
4basebio... ► Artikel lesen | |
| 15.06. | IN BRIEF: 4basebio appoints Jeff Coller to Strategic Advisory Board | 1 | Alliance News |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Mi | Century Therapeutics, Inc.: Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates | GlobeNewswire (Europe) | Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track for 4Q 2026CNTY-813... ► Artikel lesen | |
| Mi | EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Group (EN) | EQS Voting Rights Announcement: Evotec SE
Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| Mi | Hemostemix Inc.: Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell Longevity Clinical Trial | Newsfile | Calgary, Alberta--(Newsfile Corp. - August 12, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the appointment of Prof. Dr.... ► Artikel lesen | |
| Mi | Burcon NutraScience Corporation: Burcon Reports Fiscal 2027 First Quarter Results, Advances Commercial Revenue Ramp | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - August 12, 2026) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based... ► Artikel lesen | |
| Mi | Lobe Sciences Ltd. Announces Non-Brokered Private Placement | ACCESS Newswire | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / August 12, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FSE:LOBE.F) ("Lobe"... ► Artikel lesen |